A prospective, controlled phase ii study of neoadjuvant exisulind therapy before radical prostatectomy: Effect on apoptosis

Urology

Volumn 80, Issue 2, 2012, Pages 484.e17-484.e22

  Weight, Christopher J ^a   Kim, Simon P ^a   Karnes, R Jeffrey ^a   Bergstralh, Eric J ^a   Cheville, John C ^a   Leibovich, Bradley C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEINASE ACTIVATED RECEPTOR 4; SULINDAC SULFONE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG TOLERABILITY; GLEASON SCORE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; SINGLE BLIND PROCEDURE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

EID: 84864606596     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.02.027     Document Type: Article

References (28)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. Z. Petrovich, L. Baert, M.A. Bagshaw Adenocarcinoma of the prostate: innovations in management Am J Clin Oncol 20 1997 111 119
3. F.H. Schröder, J. Hugosson, M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
4. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
5. Auvinen A, de Koning HJ, Coebergh JW. Foreword: meeting the challenge of prostate cancer. Eur J Cancer. 46:3037 - 3039.
6. H. Zincke, J.E. Oesterling, M.L. Blute Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850 1857
7. J.G. Trapasso, J.B. deKernion, R.B. Smith The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy J Urol 152 1994 1821 1825
8. P.L. Marr, E.P. Elkin, S.A. Arredondo Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE J Urol 175 2006 1326 1331
9. D.G. Bostwick, H.B. Burke, T.M. Wheeler The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials J Cell Biochem Suppl 19 1994 283 289
10. F.J. Bianco, P.T. Scardino, J.A. Eastham Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (" trifecta") Urology 66 2005 83 94
11. D.K. Ornstein, J.W. Colberg, K.S. Virgo Evaluation and management of men whose radical prostatectomies failed: results of an international survey Urology 52 1998 1047 1054
12. D.S. Alberts, D.J. Garcia An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies J Nutr 125 1995 692S 697S
13. G.J. Kelloff, J.R. Johnson, J.A. Crowell Approaches to the development and marketing approval of drugs that prevent cancer Cancer Epidemiol Biomarkers Prev 4 1995 1 10
14. G.A. Piazza, A.K. Rahm, T.S. Finn Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction Cancer Res 57 1997 2452 2459
15. J.T. Lim, G.A. Piazza, E.K. Han Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines Biochem Pharmacol 58 1999 1097 1107
16. H.J. Thompson, C. Jiang, J. Lu Sulfone metabolite of sulindac inhibits mammary carcinogenesis Cancer Res 57 1997 267 271
17. G.A. Piazza, D.S. Alberts, L.J. Hixson Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res 57 1997 2909 2915
18. E.T. Goluboff, D. Prager, D. Rukstalis Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy J Urol 166 2001 882 886
19. H. Li, L. Liu, M.L. David Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation Biochem Pharmacol 64 2002 1325 1336
20. J.T. Lim, A.K. Joe, M. Suzui Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells Clin Cancer Res 12 2006 3478 3484
21. J.T. Lim, G.A. Piazza, R. Pamukcu Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells Clin Cancer Res 9 2003 4972 4982
22. L. Liu, H. Li, T. Underwood Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells J Pharmacol Exp Ther 299 2001 583 592
23. B. Zhu, L. Vemavarapu, W.J. Thompson Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells J Cell Biochem 94 2005 336 350
24. E.T. Goluboff, A. Shabsigh, J.A. Saidi Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis Urology 53 1999 440 445
25. E.T. Goluboff Exisulind, a selective apoptotic antineoplastic drug Expert Opin Investig Drugs 10 2001 1875 1882
26. S.M. Schmid, L.A. Kraus, D.G. Gordon Growth inhibitory activity of FGN-1 and analogues in 13 human tumor lines of various histogenesis Proc Am Assoc Cancer Res 39 1998 195
27. W.J. Thompson, L. Liu, M. Lloyd Apoptosis in human prostate cancer cells shows enhanced sensitivity to taxol in the presence of exisulind Ann Oncol 118 2000 139
28. C. Burke, R. Van Stolk, N. Arber Exisulind prevents adenoma formation in familial adenomatous polyposis (FAP) Gastroenterology 118 4S 2000 A657